Galimedix Therapeutics, Inc.’s Post

Women have long been underrepresented in clinical heart research — leading to gaps in detecting, treating, and setting standards of care for heart disease. Further, published data shows that women are up to 35% less likely than men to receive either of the available treatment options (TAVR and SAVR) to treat aortic stenosis.¹﹐² Earlier this month, we hosted a powerful roundtable discussion focused on reshaping the future of women’s heart health. We saw clinicians, patient advocates, and policy leaders all come together in one space to work towards the same goal - elevating the future of women’s health. This comes on the heels of #SMARTtrial data showing that Evolut™️ #TAVR delivers superior valve performance in women with a small annulus at 1 year versus SAPIEN™* platform.³ At Medtronic, we will continue helping empower and amplify the voices of women while driving awareness on women’s heart valve disease and #AorticStenosis. Huge thanks to WomenHeart: The National Coalition for Women with Heart Disease Women As One HeartValveSurgery.com and The Atlantic or your commitment to women’s heart health and partnership for this event! Watch the event replay here: https://lnkd.in/ghsc36_G #WomensHealth #HeartHealth 1. Paquin A, et al. Can J Cardiol. 2021;37:E2. 2. Rice CT, et al. Open Heart. 2023;10:e002371. 3. Herrmann HC, et al. N Engl J Med. Published online April 7, 2024. Valve performance defined as freedom from bioprosthetic valve dysfunction. Risk info: https://bit.ly/3zfF6r8 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and the need for a permanent pacemaker.

"We are confident that expanding access to the EsoGuard test will empower providers with an essential triage for upper endoscopy (EGD) that enables the early detection of BE," wrote Reginald Bell, M.D., FACS, the Chair of the American Foregut Society Board, on behalf the society. "The goal of early BE detection is to facilitate prompt treatment and surveillance, ultimately reducing the risk of cancer progression. By being available as a point-of-care test in primary care offices, EsoGuard directly reduces health disparities in endoscopy access, aligning with the mission of the American Foregut Society. We urge you to consider the immediate coverage of the EsoGuard test." Read more: https://lnkd.in/gnSn2zbi #EarlyDetectionSaveLives #Healthcare

Women have long been underrepresented in clinical heart research — leading to gaps in detecting, treating, and setting standards of care for heart disease. Further, published data shows that women are up to 35% less likely than men to receive either of the available treatment options (TAVR and SAVR) to treat aortic stenosis.¹﹐² Earlier this month, we hosted a powerful roundtable discussion focused on reshaping the future of women’s heart health. We saw clinicians, patient advocates, and policy leaders all come together in one space to work towards the same goal - elevating the future of women’s health. This comes on the heels of #SMARTtrial data showing that Evolut™️ #TAVR delivers superior valve performance in women with a small annulus at 1 year versus SAPIEN™* platform.³ At Medtronic, we will continue helping empower and amplify the voices of women while driving awareness on women’s heart valve disease and #AorticStenosis. Huge thanks to WomenHeart: The National Coalition for Women with Heart Disease, Women As One, https://bit.ly/4eEtEFM and The Atlantic for your commitment to women’s heart health and partnership for this event! Watch the event replay here: https://bit.ly/3KXwEPD #WomensHealth #HeartHealth 1. Paquin A, et al. Can J Cardiol. 2021;37:E2. 2. Rice CT, et al. Open Heart. 2023;10:e002371. 3. Herrmann HC, et al. N Engl J Med. Published online April 7, 2024. Valve performance defined as freedom from bioprosthetic valve dysfunction. Risk info: https://bit.ly/3XxpARq TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and the need for a permanent pacemaker.

Regular medical tests are essential for cancer prevention and early diagnosis. Screenings like mammograms, colonoscopies, and blood tests can detect cancer in its earliest stages, increasing the chances of successful treatment. Don’t wait—schedule your routine check-ups and encourage others to do the same. Prevention starts with knowledge and action! Contact a Lonfin Group Specialist. We do individual and Corporate Wellness Events to support you and your business. If you want to know more about your Medical Aid and if they can support preventative care, DM Andrew Govender Lonfin Wealth Bluestar Financial Advisory Services-Authorised by Sanlam #CancerAwareness #EarlyDetection #ScreeningsSaveLives #PreventionIsKey #HealthMatters #GetTested #StayInformed #FightCancer

Women have long been underrepresented in clinical heart research — leading to gaps in detecting, treating, and setting standards of care for heart disease. Further, published data shows that women are up to 35% less likely than men to receive either of the available treatment options (TAVR and SAVR) to treat aortic stenosis.¹﹐² Earlier this month, we hosted a powerful roundtable discussion focused on reshaping the future of women’s heart health. We saw clinicians, patient advocates, and policy leaders all come together in one space to work towards the same goal - elevating the future of women’s health. This comes on the heels of #SMARTtrial data showing that Evolut™️ #TAVR delivers superior valve performance in women with a small annulus at 1 year versus SAPIEN™* platform.³ At Medtronic, we will continue helping empower and amplify the voices of women while driving awareness on women’s heart valve disease and #AorticStenosis. Huge thanks to WomenHeart: The National Coalition for Women with Heart Disease, Women As One, https://bit.ly/4cmUTCG and The Atlantic for your commitment to women’s heart health and partnership for this event! Watch the event replay here: https://bit.ly/4es6lih #WomensHealth #HeartHealth 1. Paquin A, et al. Can J Cardiol. 2021;37:E2. 2. Rice CT, et al. Open Heart. 2023;10:e002371. 3. Herrmann HC, et al. N Engl J Med. Published online April 7, 2024. Valve performance defined as freedom from bioprosthetic valve dysfunction. Risk info: https://bit.ly/4eC7cNt TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and the need for a permanent pacemaker.

As of October 8th, 2024, people aged 40-49 can now self-refer for publicly funded mammograms through the Ontario Breast Screening Program (OBSP). When you call 1-800-668-9304, someone will ask you for details and then connect you with a local screening office to book your time for your mammogram. Things to remember before you go: 👉🏼 Do not wear deodorant. 👉🏼 Do not wear lotion. If you forget, they will have you wash it off before your imaging. Even if you're not experiencing any concerns, it's crucial to establish a baseline for your health. Have you booked your mammogram yet? Remember, October is #BreastCancerAwarenessMonth! We can all do our part to spread the word about this important new service. Tag your friends below! For more information visit: https://lnkd.in/gW7MHHTs

On September 29th we celebrated World Heart Day! ❤️ It is now a known fact that Cardiovascular Diseases are the number 1 cause of deaths all over the world. And while prevention is crucial, here at Virtonomy.io, we believe that advancing treatment is equally important. On this #WorldHeartDay, we reaffirm our commitment to shaping a future where heart disease is treated more effectively and life-saving solutions reach patients faster. 🎯   And this is how we tackle this problem:   ☑ Providing 3D models of underrepresented patient groups to increase device population coverage. 〰 One of our key missions is to extend our database of digital patient twins with 3D models representing underrepresented groups—including women, geriatric patients, those with rare diseases, and pediatric patients. These groups are often overlooked in traditional medical device testing, which can lead to delays in getting the best solutions to those who need them most.   By including a wider range of anatomical models, we're ensuring that cardiovascular devices are better designed, tested, and tailored for every individual—no matter their age, sex, or condition. This means faster innovations, more personalized care, and a step closer to making effective treatments accessible to all.   ☑ Enabling faster time-to-market, bringing innovative devices to patients in a shorter time frame. 〰 With our innovative platform, cardiovascular device developers can virtually implant their devices into these diverse digital models, allowing them to validate and optimize designs before entering costly and time-consuming clinical trials. This approach not only ensures that devices are safe and effective for a wide range of patients but also enables faster time-to-market, bringing innovative devices to patients in a shorter time frame.   📢 So this year we would like to take this opportunity to highlight the importance of making healthcare inclusive, efficient, and accessible. With new technologies such as #digitaltwins and #computersimulations, this is easier than ever, and it is our shared responsibility to prove that every heart matters. 💟 #medtech #digitalhealth #clinicaltrials #virtonomy

Women have long been underrepresented in clinical heart research — leading to gaps in detecting, treating, and setting standards of care for heart disease. Further, published data shows that women are up to 35% less likely than men to receive either of the available treatment options (TAVR and SAVR) to treat aortic stenosis.¹﹐² Earlier this month, we hosted a powerful roundtable discussion focused on reshaping the future of women’s heart health. We saw clinicians, patient advocates, and policy leaders all come together in one space to work towards the same goal - elevating the future of women’s health. This comes on the heels of #SMARTtrial data showing that Evolut™️ #TAVR delivers superior valve performance in women with a small annulus at 1 year versus SAPIEN™* platform.³ At Medtronic, we will continue helping empower and amplify the voices of women while driving awareness on women’s heart valve disease and #AorticStenosis. Huge thanks to WomenHeart: The National Coalition for Women with Heart Disease Women As One HeartValveSurgery.com and The Atlantic or your commitment to women’s heart health and partnership for this event! Watch the event replay here: https://bit.ly/3KXhY36 #WomensHealth #HeartHealth 1. Paquin A, et al. Can J Cardiol. 2021;37:E2. 2. Rice CT, et al. Open Heart. 2023;10:e002371. 3. Herrmann HC, et al. N Engl J Med. Published online April 7, 2024. Valve performance defined as freedom from bioprosthetic valve dysfunction. Risk info: https://bit.ly/4cC9slM TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and the need for a permanent pacemaker.

Evangelical Community Hospital, through Imaging Services, is offering a new screening exam beginning in June for prevention of heart attack and stroke. The Cardiac CT (computed tomography) Calcium Score Screening exam is most helpful for people who don’t have a clear high or clear low risk of heart attack or stroke. The test, which is quick and noninvasive, looks specifically at how much calcified (hard) plaque is in the coronary arteries. A high score of calcium in the heart’s arteries identifies an issue of plaque that can narrow or block artery function and be an indicator of atherosclerosis (coronary artery disease) which can lead to heart attack or stroke. Cardiac CT Calcium Scoring uses detailed images of the heart to calculate a score based on factors such as age, race, and gender. Learn more at ➤ https://ow.ly/NEGT50Sc4r8 #HeartHealth #StrokePrevention #CardiacHealth #PreventiveCare #HealthyHabits

At VedaRx, we're transforming the landscape of cardiac health with our Vedagenetics advanced genetic testing, allowing for the early identification of risks and empowering proactive health management. 1⃣ Advanced Genetic Testing: Our cutting-edge technology facilitates the early detection of potential cardiac disease risks, enabling timely intervention and personalized care strategies. 2⃣ Early Identification of Risk: By diagnosing cardiac disease risk at a curable stage, we provide a significant opportunity to prevent the progression of heart conditions and improve patient outcomes. 3⃣ Focus on Cardio Health: Cardiac health is often overlooked until it's too late. Our early assessment tools help bring attention to this critical aspect of overall well-being, emphasizing the importance of proactive health measures. 4⃣ Predictability and Prevention: Vedagenetics assessments offer insights into early lifestyle and genetic health issues, allowing individuals to take informed steps towards better heart health. Join us in our mission to revolutionize cardiac care and promote a healthier future. Together, we can make early intervention and prevention a cornerstone of heart health. #hearthealth #healthyheart #heart #cardiacmonitoring #cardiachealth #cardiacdisease #cardiac #testing #vedarx